Accordingly, anti-PD-1/PD-L1 immunotherapy has shown clinical benefits in different tumor types, such as non-small-cell lung cancer (NSCLC) [7], ovarian cancer [8], melanoma [9], and bladder cancer [10]. Here, PDCD1 is linked to non-small cell lung carcinoma.